ANIX has 36-month beta value of 0.88. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ANIX is 30.49M, and currently, short sellers hold a 1.32% ratio of that float. The average trading volume of ANIX on February 21, 2025 was 116.95K shares.
ANIX) stock’s latest price update
Anixa Biosciences Inc (NASDAQ: ANIX) has experienced a rise in its stock price by 10.45 compared to its previous closing price of 2.87. However, the company has seen a gain of 0.96% in its stock price over the last five trading days. prnewswire.com reported 2025-02-18 that Amendment expands the potential benefits of CAR-T therapy allowing a second dose and includes more ovarian cancer histologies SAN JOSE, Calif., Feb. 18, 2025 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that it, along with its partner Moffitt Cancer Center (“Moffitt”), has received approval for an amendment to the protocol governing its ongoing clinical trial using CAR-T therapy for the treatment of ovarian cancer (NCT05316129).
ANIX’s Market Performance
ANIX’s stock has risen by 0.96% in the past week, with a monthly rise of 12.81% and a quarterly rise of 2.92%. The volatility ratio for the week is 7.68% while the volatility levels for the last 30 days are 7.07% for Anixa Biosciences Inc The simple moving average for the past 20 days is 5.84% for ANIX’s stock, with a 7.43% simple moving average for the past 200 days.
Analysts’ Opinion of ANIX
Many brokerage firms have already submitted their reports for ANIX stocks, with Chardan Capital Markets repeating the rating for ANIX by listing it as a “Buy.” The predicted price for ANIX in the upcoming period, according to Chardan Capital Markets is $8 based on the research report published on December 23, 2022 of the previous year 2022.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ANIX reach a price target of $11. The rating they have provided for ANIX stocks is “Buy” according to the report published on April 12th, 2021.
ANIX Trading at 15.14% from the 50-Day Moving Average
After a stumble in the market that brought ANIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.52% of loss for the given period.
Volatility was left at 7.07%, however, over the last 30 days, the volatility rate increased by 7.68%, as shares surge +6.55% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.55% lower at present.
During the last 5 trading sessions, ANIX rose by +0.96%, which changed the moving average for the period of 200-days by +6.73% in comparison to the 20-day moving average, which settled at $3.00. In addition, Anixa Biosciences Inc saw 36.64% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ANIX starting from Baskies Arnold M, who purchase 5,000 shares at the price of $2.82 back on Jan 28 ’25. After this action, Baskies Arnold M now owns 120,000 shares of Anixa Biosciences Inc, valued at $14,100 using the latest closing price.
Titterton Lewis H jr, the Director of Anixa Biosciences Inc, purchase 2,000 shares at $2.91 during a trade that took place back on Jan 23 ’25, which means that Titterton Lewis H jr is holding 932,334 shares at $5,820 based on the most recent closing price.
Stock Fundamentals for ANIX
The total capital return value is set at -0.72. Equity return is now at value -56.63, with -53.29 for asset returns.
Based on Anixa Biosciences Inc (ANIX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -31.62.
Currently, EBITDA for the company is -13.83 million with net debt to EBITDA at 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.54.
Conclusion
To put it simply, Anixa Biosciences Inc (ANIX) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
